Concepedia

Paul A. Escarpe

PA

Statistics

Publications

16

Citations

2.1K

H-Index

15

Active since

1997

Affiliations

Gilead Sciences (United States)(Current)

Roche (United Kingdom)

Australian National University

University of Birmingham

University of California, Berkeley

Paul A. Escarpe is an author at Gilead Sciences (United States) specializing in pharmacology, pharmacy, and drug discovery.

Publications per year

1997–2017

16

Publications

16

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

Laura R. Saunders, Alexander J. Bankovich, Wade Anderson et al. · Science Translational Medicine · 2015 · 578 citations

, , +17

Structure−Activity Relationship Studies of Novel Carbocyclic Influenza Neuraminidase Inhibitors

Choung U. Kim, Willard Lew, Matthew A. Williams et al. · Journal of Medicinal Chemistry · 1998 · 290 citations · Full text

, , +15

Oral Administration of a Prodrug of the Influenza Virus Neuraminidase Inhibitor GS 4071 Protects Mice and Ferrets against Influenza Infection

Dirk B. Mendel, Chun Y. Tai, Paul A. Escarpe et al. · Antimicrobial Agents and Chemotherapy · 1998 · 255 citations · Full text

, , +12

Identification of GS 4104 as an Orally Bioavailable Prodrug of the Influenza Virus Neuraminidase Inhibitor GS 4071

Weixing Li, Paul A. Escarpe, Eugene Eisenberg et al. · Antimicrobial Agents and Chemotherapy · 1998 · 224 citations · Full text

, , +14

A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions

Marc Damelin, Alexander J. Bankovich, Jeffrey Bernstein et al. · Science Translational Medicine · 2017 · 157 citations

, , +16

1–5 of 16